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INTRODUCTION
Deafness is a global public health concern that affects 1 to 3 
per 1,000 newborns.1 In more than half of the cases of con-
genital or prelingual deafness, the cause is genetic, and most 
demonstrate an autosomal recessive inheritance pattern.1 
Mutations in 58 different genes have been reported to cause 
autosomal recessive nonsyndromic deafness (ARNSD) (http:// 
hereditaryhearingloss.org).
Except for one relatively common gene, GJB2 (MIM 
121011), most reported mutations are present in only a sin-
gle or a small number of families.2 Whole-exome sequenc-
ing (WES) allows resequencing of nearly all exons of the 
protein-coding genes in the genome.3 A growing number 
of research and clinical diagnostic laboratories are success-
fully using WES for gene/variant identification because of 
its comprehensive analysis advantages.4,5 In this study, we 
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Purpose: Autosomal recessive nonsyndromic deafness (ARNSD) is 
characterized by a high degree of genetic heterogeneity, with reported 
mutations in 58 different genes. This study was designed to detect 
deafness-causing variants in a multiethnic cohort with ARNSD by 
using whole-exome sequencing (WES).
Methods: After excluding mutations in the most common gene, 
GJB2, we performed WES in 160 multiplex families with ARNSD 
from Turkey, Iran, Mexico, Ecuador, and Puerto Rico to screen for 
mutations in all known ARNSD genes.
Results: We detected ARNSD-causing variants in 90 (56%) families, 
54% of which had not been previously reported. Identified mutations 
were located in 31 known ARNSD genes. The most common genes 
with mutations were MYO15A (13%), MYO7A (11%), SLC26A4 
(10%), TMPRSS3 (9%), TMC1 (8%), ILDR1 (6%), and CDH23 
(4%). Nine mutations were detected in multiple families with shared 
 haplotypes, suggesting founder effects.
Conclusion: We report on a large multiethnic cohort with ARNSD 
in which comprehensive analysis of all known ARNSD genes 
 identifies causative DNA variants in 56% of the families. In the 
remaining  families, WES allows us to search for causative variants 
in novel genes, thus improving our ability to explain the underlying 
etiology in more families.
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present the results of WES in a large multiethnic cohort con-
sisting of 160 families with ARNSD who were negative for 
GJB2 mutations.
MATeRIALs AND MeTHODs
statement of ethics
This study was approved by the University of Miami Institutional 
Review Board (USA), the Ankara University Medical School 
Ethics Committee (Turkey), the Growth and Development 
Research Ethics Committee (Iran), the Bioethics Committee of 
FFAA (HE-1) in Quito (Ecuador), and the Ethics Committee 
of National Institute of Rehabilitation (Mexico). A signed 
informed-consent form was obtained from each participant or, 
in the case of a minor, from the parents.
subjects
We included 160 families with at least two members with 
nonsyndromic sensorineural hearing loss with a pedigree 
structure suggestive of autosomal recessive inheritance 
(affected siblings born to unaffected parents with or with-
out parental consanguinity); GJB2 mutations were negative. 
Hearing loss was congenital or prelingual-onset with a sever-
ity ranging from mild to profound. The study comprised 
101 families from Turkey, 54 from Iran, 2 from Mexico, 2 
from Ecuador, and 1 from Puerto Rico. Sensorineural hear-
ing loss was diagnosed via standard audiometry in a sound-
proof room according to standard clinical practice. Clinical 
evaluation of all affected individuals by a geneticist and an 
otolaryngologist included a thorough physical examina-
tion, otoscopy, and ophthalmoscopy. Tandem walking and 
the Romberg test were used for initial vestibular evalua-
tion, with more detailed tests if needed based on symptoms 
and findings. Laboratory investigation included, but was 
not limited to, an electrocardiogram, urinalysis, and, when 
available, a  high-resolution computed tomography (CT) 
scan of the temporal bone or magnetic resonance imaging 
(MRI) to identify inner ear anomalies. DNA was extracted 
from peripheral leukocytes of each member of the family by 
standard protocols.
Whole-exome sequencing
Agilent SureSelect Human All Exon 50 Mb versions 3, 4, and 
5 (Agilent Technologies Santa Clara, CA) were used for in-
solution enrichment of coding exons and flanking intronic 
sequences following the manufacturer’s standard protocol. 
The enriched DNA samples were subjected to standard sam-
ple preparation for the HiSeq 2000 instrument (Illumina San 
Diego, CA). The Illumina CASAVA v1.8 pipeline was used to 
produce 99-bp sequence reads. The Burrows-Wheeler Aligner6 
(http://bio-bwa.sourceforge.net) was used to align sequence 
reads to the human reference genome (hg19), and variants 
were called using the GATK (https://www.broadinstitute. 
org/gatk/) software package.7 All  single-nucleotide variants 
(SNVs) and insertion/deletions (INDELs) were submitted to 
Figure 1 Overall workflow of our Wes pipeline. CNV, copy-number variation; INDEL, insertion/deletion; SNV, single-nucleotide variant; WES, whole-exome 
sequencing.
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Table 1 Mutations identified in known ARNSD genes
Family ID
Country of 
origin Genotype cDNA Protein NM transcript Gene Reference
543 Turkey Homozygous c.4441T>C p.S1481P NM_016239.3 MYO15A Cengiz et al.23
724 Turkey Homozygous c.4652C>A p.A1551D NM_016239.3 MYO15A Diaz-Horta et al.4
765 Turkey Homozygous c.4273C>T p.Q1425X NM_016239.3 MYO15A Diaz-Horta et al.4
723 Turkey Homozygous c.8307_8309delGGA p.E2770del NM_016239.3 MYO15A Novel
795 Turkey Homozygous c.5808_5814delCCGTGGC p.R1937TfsX10 NM_016239.3 MYO15A Cengiz et al.23
793 Turkey Homozygous c.5808_5814delCCGTGGC p.R1937TfsX10 NM_016239.3 MYO15A Cengiz et al.23
1209 Puerto Rico Heterozygous c.7226delC p.P2409QfsX8 NM_016239.3 MYO15A Novel
Heterozygous c.9620G>A p.R3207H NM_016239.3 MYO15A Novel
1083 Turkey Homozygous c.5183T>C p.L1728P NM_016239.3 MYO15A Novel
1332 Turkey Homozygous c.10361delT p.V3454GfsX5 NM_016239.3 MYO15A Novel
489 Turkey Homozygous c.5286_5287delTC p.R1763AfsX45 NM_016239.3 MYO15A Novel
1023 Iran Homozygous c.8638_8641delCCTG p.P2880RfsX19 NM_016239.3 MYO15A Novel
862 Turkey Heterozygous c.7894G>T p.V2632L NM_016239.3 MYO15A Novel
Heterozygous c.5133 + 1G>A splice NM_016239.3 MYO15A Novel
974 Iran Homozygous c.6487G>A p.G2163S NM_000260.3 MYO7A Janecke et al.24
1391 Turkey Homozygous c.6487G>A p.G2163S NM_000260.3 MYO7A Janecke et al.24
435 Turkey Homozygous c.3935T>C p.L1312P NM_000260.3 MYO7A Novel
472 Turkey Homozygous c.1556G>T p.G519V NM_000260.3 MYO7A Novel
1370 Turkey Homozygous c.722G>A p.R241H NM_000260.3 MYO7A Cremers et al.25
432 Turkey Homozygous c.5362_5363delAG p.R1788DfsX13 NM_000260.3 MYO7A Novel
637 Turkey Heterozygous c.5838delT p.F1946LfsX24 NM_000260.3 MYO7A Novel
Heterozygous c.5573T>C p.L1858P NM_000260.3 MYO7A Bharadwaj et al.26
996 Iran Homozygous c.5785C>T p.Q1929X NM_000260.3 MYO7A Novel
1019 Iran Homozygous c.1708C>T p.R570X NM_000260.3 MYO7A Yoshimura et al.27
1404 Turkey Heterozygous c.1708C>T p.R570X NM_000260.3 MYO7A Yoshimura et al.27
Heterozygous c.6025G>A p.A2009T NM_000260.3 MYO7A Novel
786 Turkey Homozygous c.1001G>T p.G334V NM_000441.1 SLC26A4 Landa et al.28
634 Turkey Homozygous c.1001G>T p.G334V NM_000441.1 SLC26A4 Landa et al.28
1418 Turkey Homozygous c.1061T>C p.F354S NM_000441.1 SLC26A4 Blons et al.29
238 Turkey Homozygous c.1226G>A p.R409H NM_000441.1 SLC26A4 Van Hauwe et al.30
973 Iran Homozygous c.1334T>G p.L445W NM_000441.1 SLC26A4 Van Hauwe et al.30
905 Turkey Homozygous c.2168A>G p.H723R NM_000441.1 SLC26A4 Van Hauwe et al.30
1417 Turkey Heterozygous c.665G>A p.G222D NM_000441.1 SLC26A4 Novel
Heterozygous c.1198delT p.C400VfsX32 NM_000441.1 SLC26A4 Novel
1346 Turkey Homozygous c.919-2A>G splice NM_000441.1 SLC26A4 Coucke et al.31
1321 Turkey Homozygous c.1198delT p.C400VfsX32 NM_000441.1 SLC26A4 Novel
395 Turkey Homozygous c.36dupC p.F13LfsX10 NM_024022.2 TMPRSS3 Diaz-Horta et al.4
777 Turkey Homozygous c.913A>T p.I305F NM_024022.2 TMPRSS3 Novel
674 Turkey Homozygous c.271C>T p.R91X NM_024022.2 TMPRSS3 Novel
629 Turkey Homozygous c.399G>C p.W133C NM_024022.2 TMPRSS3 Novel
1368 Turkey Homozygous c.1126G>A p.G376S NM_024022.2 TMPRSS3 Novel
1410 Turkey Homozygous c.436G>A p.G146S NM_024022.2 TMPRSS3 Novel
910 Turkey Homozygous c.616G>T p.A206S NM_024022.2 TMPRSS3 Novel
633 Turkey Homozygous c.616G>T p.A206S NM_024022.2 TMPRSS3 Novel
52 Turkey Homozygous c.1589_1590CT p.S530X NM_138691.2 TMC1 Hildebrand et al.32
123 Turkey Homozygous c.1080_1084delGATCA p.R362PfsX6 NM_138691.2 TMC1 Novel
662 Turkey Homozygous c.2050G>A p.D684N NM_138691.2 TMC1 Novel
1268 Ecuador Heterozygous c.1718T>A p.I573N NM_138691.2 TMC1 Novel
Heterozygous c.2130-1delG splice NM_138691.2 TMC1 Novel
911 Turkey Homozygous c.1534C>T p.R512X NM_138691.2 TMC1 Kurima et al.33
490 Turkey Homozygous c.1959C>G p.Y653X NM_138691.2 TMC1 Novel
Table 1 Continued on next page
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393 Turkey Heterozygous c.63 + 2T>A splice NM_138691.2 TMC1 Duman et al.18
Heterozygous c.236 + 1G>A splice NM_138691.2 TMC1 Duman et al.18
988 Iran Homozygous c.3215C>A p.A1072D NM_022124.5 CDH23 Duman et al.18
1165 Mexico Heterozygous c.2959G>A p.D987N NM_022124.5 CDH23 Novel
Heterozygous c.3628C>T p.Q1210X NM_022124.5 CDH23 Novel
1015 Iran Homozygous c.5851G>A p.D1951N NM_022124.5 CDH23 Novel
1032 Iran Heterozygous c.7822C>T p.R2608C NM_022124.5 CDH23 Novel
Heterozygous c.8120C>T p.P2707L NM_022124.5 CDH23 Novel
968 Iran Homozygous c.820C>T p.Q274X NM_001199799.1 ILDR1 Diaz-Horta et al.4
800 Turkey Homozygous c.942C>A p.C314X NM_001199799.1 ILDR1 Novel
799 Turkey Homozygous c.942C>A p.C314X NM_001199799.1 ILDR1 Novel
782 Turkey Homozygous c.942C>A p.C314X NM_001199799.1 ILDR1 Novel
969 Iran Homozygous c.82delG p.V28SfsX31 NM_001199799.1 ILDR1 Novel
1297 Turkey Homozygous c.5431A>T p.K1811X NM_194248.2 OTOF Romanos et al.34
98 Turkey Homozygous c.5431A>T p.K1811X NM_194248.2 OTOF Romanoset al.34
1398 Turkey Homozygous c.3679C>T p.R1227X NM_194248.2 OTOF Novel
909 Turkey Homozygous c.765G>C p.Q255H NM_194248.2 OTOF Rodríguez-
Ballesteros et al.35
725 Turkey Homozygous c.3918T>G p.C1306W NM_033056.3 PCDH15 Novel
1238 Turkey Homozygous CNV CNV NM_033056.3 PCDH15 Novel
1044 Iran Homozygous c.3101G>A p.R1034H NM_033056.3 PCDH15 Novel
1369 Turkey Homozygous c.250C>T p.R84W NM_147196.2 TMIE Naz et al.36
1354 Turkey Homozygous c.250C>T p.R84W NM_147196.2 TMIE Naz et al.36
1402 Turkey Homozygous c.250C>T p.R84W NM_147196.2 TMIE Naz et al.36
1239 Turkey Homozygous c.490-1G>T splice NM_016366.2 CABP2 Novel
1366 Turkey Homozygous c.1018G>T p.E340X NM_004452.3 ESRRB Novel
1372 Turkey Homozygous c.1018G>T p.E340X NM_004452.3 ESRRB Novel
794 Turkey Homozygous c.508C>A p.H170N NM_133261.2 GIPC3 Novel
1356 Turkey Homozygous c.508C>A p.H170N NM_133261.2 GIPC3 Novel
182 Turkey Homozygous c.4480C>T p.R1494X NM_144612.6 LOXHD1 Diaz-Horta et al.4
779 Turkey Homozygous c.2863G>T p.E955X NM_144612.6 LOXHD1 Diaz-Horta et al.4
303 Turkey Homozygous c.628A>T p.K210X NM_005709.3 USH1C Novel
994 Iran Homozygous c.876 + 2delTA splice NM_005709.3 USH1C Novel
661 Turkey Homozygous c.330T>A p.Y110X NM_006383.3 CIB2 Novel
262 Turkey Homozygous c.2662C>A p.P888T NM_080680.2 COL11A2 Chakchouk et al.37
448 Turkey Homozygous c.499C>T p.R167X NM_001042702.3 DFNB59 Collin et al.38
908 Turkey Homozygous c.102-1G>A splice NM_014722.2 FAM65B Diaz-Horta et al.17
1289 Turkey Homozygous c.2956A>T p.K986X NM_032119.3 GPR98 Novel
820 Turkey Homozygous c.79C>T p.R27X NM_001080476.2 GRXCR1 Novel
67 Turkey Homozygous c.1498C>T p.R500X NM_001038603.2 MARVELD2 Riazuddin et al.39
1364 Turkey Homozygous c.1015C>T p.R339W NM_004999.3 MYO6 Yang et al.40
63 Turkey Homozygous CNV CNV NM_144672.3 OTOA Bademci et al. 15
338 Turkey Homozygous c.1430delT p.V477EfsX25 NM_173591.3 OTOGL Yariz et al.16
1294 Turkey Homozygous c.1108C>T p.R370X NM_002906.3 RDX Novel
850 Turkey Homozygous CNV CNV NM_153700.2 STRC Bademci et al.15
1035 Iran Homozygous c.5210A>G p.Y1737C NM_005422.2 TECTA Diaz-Horta et al.4
7 Turkey Homozygous c.705_709dupCCTGC p.R237PfsX215 NM_001128228.2 TPRN Novel
23 Turkey Homozygous c.2335_2336delAG p.R785SfsX50 NM_001039141.2 TRIOBP Diaz-Horta et al.4
5 Turkey Homozygous c.387_388insC p.K130QfsX5 NM_173477.2 USH1G Novel
Families with compound heterozygous mutations are italicized.
CNV, copy-number variation.
Table 1 Continued
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SeattleSeq137 for further characterization and annotation. 
Sanger sequencing was used for confirmation and segrega-
tion of the variants in each family.
Bioinformatics analysis
We analyzed WES data using our in-house tool (https://
genomics.med.miami.edu). Our workflow is shown in 
Figure  1. The analysis started with quality control (QC) 
checks, including the coverage and average read depth of 
targeted regions, numbers of variants in different categories, 
and quality scores. All variants were annotated and catego-
rized into known and novel variants. As previously recom-
mended, we filtered variants based on minor allele frequency 
of <0.005 in dbSNP141.8 We also filtered out variants that are 
present in >10 samples in our internal database of >3,000 
exomes from European, Asian, and American ancestries 
that includes Turkish, Iranian, Mexican, Ecuadorian, and 
Puerto Rican samples (Figure  1). Autosomal recessive 
inheritance with both homozygous and compound hetero-
zygous inheritance models and a genotype quality (GQ) 
score >35 for the variant quality were chosen. Missense, 
nonsense, splice site,  in-frame INDEL, and frame-shift 
INDELs in the known ARNSD genes (Supplementary Data 
online) were selected. Missense variants that remained after 
these filters were later analyzed for presence in the Human 
Gene Mutation Database (http://www.hgmd.cf.ac.uk) and 
for having a pathogenic prediction score at least in two of 
the following tools: PolyPhen2,9 SIFT,10 MutationAssessor,11 
and MutationTaster.12 Finally, we used CoNIFER13 (Copy 
Number Inference From Exome Reads) and XHMM14 
Table 2 Overview of mutation detection and parental consanguinity
Countries
Number of  
families
Reported parental 
consanguinity
Number of homozygous  
probands (consanguineous)
Number of compound heterozygous 
probands (consanguineous)
Turkey 101 82 67 (59) 5 (2)
Iran 54 31 12 (10) 1 (1)
Ecuador 2 0 0 1 (0)
Mexico 2 0 0 1 (0)
Puerto Rico 1 0 0 1 (0)
Figure 2 Capture kit versions and coverages. (a–c) Overview of coverage of 58 known ARNSD genes according to three different versions (version 3 = V3, 
version 4 = V4, and version 5 = V5) of the exome enrichment kit. (d) Numbers of samples studied with different capture kits. ARNSD, autosomal recessive 
nonsyndromic deafness.
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(eXome-Hidden Markov Model) to detect  copy-number 
variations (CNVs).15 After this filtering, only variants cose-
gregated with the phenotype in the entire family were con-
sidered pathogenic.
ResULTs
On average, each exome had 99, 95, and 88% of mappable bases 
of the Gencode-defined exome represented by coverage of 1X, 
5X, and 10X reads, respectively. Average coverage of the map-
pable bases for the 58 known ARNSD genes (exons and the first 
and last 20 bps of introns) were 99, 95, and 87% for the 1X, 5X, 
and 10X reads, respectively.
We detected pathogenic or likely pathogenic variants that can 
explain ARNSD in 90 (56%) families. All identified variants cose-
gregated with deafness as an autosomal recessive trait. Fifty-four 
percent of the mutations were not previously reported in the 
Human Gene Mutation Database. Mutations were identified in 
31 ARNSD genes. The genes with mutations identified in at least 
three families are MYO15A (MIM 602666) (13%), MYO7A (MIM 
276903) (11%), SLC26A4 (MIM 605646) (10%), TMPRSS3 
(MIM 605551) (9%), TMC1 (MIM 606706) (8%), ILDR1  
(MIM 609739) (6%), CDH23 (MIM 605516) (4%), OTOF (MIM 
603681) (4%), PCDH15 (MIM 605514) (3%), and TMIE (MIM 
607723) (3%). During the course of this study we reported muta-
tions in OTOGL (MIM 614925) and FAM65B (MIM 611410) as 
novel causes of ARNSD16,17 (Figure 1; Table 1).
DIsCUssION
Identifying causative variants in ARNSD is challenging because 
of the following: (i) the extreme genetic heterogeneity of ARNSD; 
(ii) the presence of different categories of genetic variants such as 
SNVs, INDELs, and CNVs; (iii) the presence of a high propor-
tion of nonrecurrent mutations; and (iv) the variability in muta-
tion frequencies in individual ARNSD genes across ethnicities.18 
Consequently, we performed a comprehensive analysis to detect 
pathogenic SNVs, INDELs, and CNVs in the ARNSD genes.
Targeted resequencing allows identification of mutations in 
the interested gene sets. Recent studies pioneered by Shearer 
et al.8,19 have shown the effectiveness of the targeted resequenc-
ing of deafness genes. Advantages of the targeted resequenc-
ing over WES are having better coverage with higher depth 
and significantly lower costs, which is suitable for clinical 
diagnostic laboratories. However, a main limitation of the tar-
geted sequencing is the need for revalidation of the panel after 
adding each new gene. By contrast, many laboratories around 
the world offer WES as a diagnostic tool requiring validation 
only when a new WES version is introduced. Our analysis 
using three different versions of an exome capture kit during 
the 4-year period shows that the depth of coverage of WES has 
improved to reliably identify most mutations in known ARNSD 
genes (Figure  2; Supplementary Tables S1 and S4 online). 
Recently developed WES approaches provide more coverage 
for genes that are known to cause Mendelian disease. They are 
Figure 3 Distribution of causative DNA variants in known ARNSD genes according to the (a) family origin and (b) variant categories. ARNSD, autosomal 
recessive nonsyndromic deafness; CNV, copy-number variation.
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expected to cover deafness genes more efficiently. In addition, 
adding in baits to improve coverage over poorly covered regions 
may be considered if better coverage is desired. It was recently 
shown via targeted sequencing that CNVs are a common cause 
of deafness.20 Although CNV analysis of the WES data is still 
being optimized for clinical usage, we integrated two currently 
available tools—XHMM and CoNIFER—into our WES analy-
sis pipeline and identified large OTOA (MIM 607038), STRC 
(MIM 606440), and PCDH15 (exon 27–28) homozygous dele-
tions in our cohort, supporting a significant role of CNVs in 
deafness etiology.
In this study, after excluding GJB2 mutations we detected 
pathogenic variants in the known ARNSD genes in 56% of the 
families. The advantage of this study is having large multiplex 
autosomal recessive families (including affected and unaffected 
children) who can be tested for cosegregation of all variants. 
While we identified more novel variants than those reported in 
Table 1 through WES, only those variants cosegregated in the 
family with deafness were considered pathogenic. Similarly het-
erozygous variants did not explain the phenotype because they 
did not cosegregate with deafness and were not included. WES 
facilitates the cataloging of mutations in different populations. 
Population characteristics such as the rate of consanguineous 
marriages may affect the distribution of deafness mutations in 
different populations. As expected, the vast majority of Turkish 
and Iranian probands from consanguineous marriages are homo-
zygous for the pathogenic variants (Table 2). However, there is a 
marked difference between the rates of solved families in Turkey 
(73%) versus Iran (24%) (Figure 3). As shown in Figure 3, the 
distribution of genes is also different between the two countries. 
In our study, the top five genes explain 39 of 101 families (39%) 
in Turkey, whereas they explained only 10 of 54 families (19%) 
in Iran. Moreover, our analysis of the WES data in the unsolved 
Iranian families shows that there are no common mutations in 
genes that are not known to be deafness genes (data not shown). 
Unless there are common mutations in regions that are not well 
covered by WES, our data suggest that many rare genes are 
responsible for the majority of hereditary deafness in the Iranian 
cohort. It is likely that there are undetected rare variants specific 
to certain ethnicities in Iran.21 Another advantage of WES is 
that surveying of mutations for founder effects is possible. We 
detected TMIE c.250C>T (p.R84W) in three unrelated Turkish 
families that all shared a flanking haplotype as noted previously.22 
Furthermore, MYO15A, MYO7A, SLC26A4, TMPRSS3, ILDR1, 
OTOF, ESRRB (MIM 602167), and GIPC3 (MIM 608792) genes 
had recurrent mutations with shared haplotypes, indicating 
founder effects (Supplementary Table S2 online).
There is no correlation between the size of transcript and 
number of mutant alleles (Supplementary Table S3 online). 
There may be some deafness genes that are more prone to having 
mutations. Founder effects appear to play a role because some 
small genes such as TMIE, ESRRB, and GIPC3 ranked high in 
mutation frequency because of founder mutations. Some dis-
crepancy between the size of a gene and number of mutations 
can be explained by the fact that only certain mutations cause 
nonsyndromic deafness for some genes. For instance, CDH23, 
PCDH15, and MYO7A are big genes, but many mutations in 
those genes cause Usher syndrome (MIM 276900) instead of 
ARNSD. An interesting example is TMC1, which ranks 20th 
based on size but 5th in mutation frequency. Nonsyndromic 
deafness is the only phenotype caused by TMC1 mutations, and 
none of the TMC1 mutations is recurrent in our cohort. These 
may suggest that TMC1 is relatively more prone to have de novo 
mutations or that it is a highly conserved gene and its variants 
are rarely tolerated.
In conclusion, WES is an effective tool for identifying patho-
genic SNVs, INDELs, and CNVs simultaneously in ARNSD 
genes and provides further analysis of the families without 
mutations for novel gene discovery. Identification of two novel 
ARNSD genes16,17 during the course of this study testifies to its 
power.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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